Active, not recruitingPhase 3NCT03673501
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
Studying Gastrointestinal stromal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Deciphera Pharmaceuticals, LLC
- Intervention
- Ripretinib(drug)
- Enrollment
- 453 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2026
Study locations (30)
- Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
- University of California San Diego Medical Center, La Jolla, California, United States
- UCLA Hematology Oncology Center - Main Site, Los Angeles, California, United States
- Stanford Medicine, Stanford, California, United States
- University of Colorado Hospital - Anschutz Cancer Pavillion, Aurora, Colorado, United States
- Rocky Mountain Cancer Centers, Denver, Colorado, United States
- Smilow Cancer Hospital at Yale, New Haven, Connecticut, United States
- Washington Cancer Institute at MedStar Washington Hospital Center, Washington D.C., District of Columbia, United States
- Mayo Clinic Florida, Jacksonville, Florida, United States
- Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
- Orlando Health UF Health Cancer Center, Orlando, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Winship Cancer Institute, Atlanta, Georgia, United States
- Georgia Cancer Specialists, Sandy Springs, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03673501 on ClinicalTrials.govOther trials for Gastrointestinal stromal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07171203Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal TumorUniversity of California, San Diego
- RECRUITINGNANCT07405125Safety of Robotic Surgery for GISTs at Special Anatomic SitesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE3NCT07218926A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyGlaxoSmithKline
- RECRUITINGPHASE1NCT06655246A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)Kura Oncology, Inc.
- RECRUITINGNANCT06926374Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic SurgeryChinese University of Hong Kong
- RECRUITINGNANCT07411118RCT of EFTR Versus STER for GIST TreatmentChinese University of Hong Kong
- RECRUITINGPHASE1, PHASE2NCT06630234A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)Deciphera Pharmaceuticals, LLC
- RECRUITINGPHASE3NCT06640361A Study of Olverembatinib in SDH-deficient GIST.Ascentage Pharma Group Inc.